Alkami price target lowered to $28 from $40 at Citizens

Citizens analyst Patrick Walravens lowered the firm’s price target on Alkami (ALKT) to $28 from $40 and keeps an Outperform rating on the shares. The company reported strong Q4 results, but guidance was disappointing, the analyst tells investors in a research note. The firm still likes the stock here and thinks the underlying business is healthy.